EUCTR2004-002594-23-DE进行中（未招募）不适用
A randomized, double-blind, vehicle-controlled, half-side comparison, monocenter, clinical study evaluating the efficacy and safety of a herbal dermatitis ointment for the treatment of mild to moderate atopic dermatitis
Weber & Weber GmbH & Co.KG0 个研究点开始时间: 2005年1月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Caucasian males and females betwen 18 and 65 years of age with mild to moderate atopic dermatitis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of glucocorticoids 4 weeks prior to study entry
- •Systemic use of antihistamines, antipruritics or immunosuppressants 2 weeks prior to study entry
- •Any treatment of target area for at least 2 weeks prior to study entry
研究者
相似试验
已完成
3 期
A randomized, double-blind, vehicle-controlled, parallel-group trial to assess the efficacy, safety and tolerability of P-3073 for topical treatment of nail psoriasisPsoriasis vulgarisail PsoriasisL40.0DRKS00009547Polichem SA378
进行中（未招募）
不适用
A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facial acne vulgaris - FR260500 proof of concept acneEUCTR2004-002842-37-GBFujisawa GmbH66
进行中（未招募）
不适用
A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facial acne vulgaris - FR260500 proof of concept acneMild to moderate facial acne vulgaris.MedDRA version: 7.0Level: LLTClassification code 10000519EUCTR2004-002842-37-DEFujisawa GmbH66
已完成
不适用
A double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopeciaAndrogenetic alopecia.Skin and Connective Tissue DiseasesAndrogenetic alopeciaISRCTN49873657ProStrakan Pharmaceuticals (France)60
进行中（未招募）
1 期
A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients with facial acne vulgarisfacial acne vulgarisMedDRA version: 20.0Level: PTClassification code 10000496Term: AcneSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2018-003307-19-DEPPM SERVICES S.A.450